MedPath

Nocturnal Oxygen Treatment in Heart Failure and Cheyne-Stokes Respiration

Not Applicable
Completed
Conditions
Heart Failure
Registration Number
NCT00338078
Lead Sponsor
Umeå University
Brief Summary

The purpose of this study is to determine whether oxygen therapy during sleep improves quality of life, exercise capacity and heart function among patients with chronic heart failure and central sleep apnea.

Detailed Description

Oxygen therapy reduces the number of central apneas among patients with congestive heart failure but it is unknown whether quality of life and heart function also improve. We aim to test whether the quality of life, exercise capacity and heart function are improved with nocturnal oxygen therapy during 6 weeks with nocturnal oxygen from oxygen concentrator or nocturnal air from placebo concentrator.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
62
Inclusion Criteria
  • Stable heart failure with left ventricular dysfunction
  • Cheyne-Stokes respiration with central AHI>15 and obstructive AHI<5
Exclusion Criteria
  • Heart infarction within 3 months.
  • Dementia
  • Chronic obstructive pulmonary disease and daytime hypoxemia.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Exercise capacity
Quality of life (SF-36, Minnesota, Living with heart failure questionnaire)
Brain natriuretic peptide (BNP)
Secondary Outcome Measures
NameTimeMethod
Echocardiography
Radionuclide determination of ejection fraction
Mortality and hospitalization for cardiovascular causes (combined and individually)
Hospitality anxiety and depression scale
Epworth sleepiness scale
Karolinska sleepiness scale
Routine lab (haemoglobins, thyroid status, creatinin)
Urinary catecholamines
Urinary cortisol
Polysomnography
Arrhythmias from 24 hour Holter-ECG registration
Heart rate variability

Trial Locations

Locations (1)

Dept of respiratory medicine

🇸🇪

Umeå, Sweden

© Copyright 2025. All Rights Reserved by MedPath